SBC Medical Group Holdings (NASDAQ:SBC), a leading Management Services Organization (MSO) for a diverse range of medical franchises, today announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025.
Kiora Pharmaceuticals (NASDAQ:KPRX) released its fourth-quarter and full-year 2025 financial results on Wednesday, detailing a streamlined balance sheet and steady clinical momentum for its pipeline of retinal disease treatments.
Sanara MedTech (NASDAQ:SMTI) today announced its financial results for the fourth quarter and full year ended December 31, 2025, marking the first time the company has surpassed the $100 million annual revenue threshold.
Neurogene (NASDAQ:NGNE) today reported financial results for the fourth quarter and full year ended December 31, 2025, delivering a "beat" against Wall Street’s bottom-line expectations.
LENZ Therapeutics (NASDAQ:LENZ) today reported its financial results for the fourth quarter and full year ended December 31, 2025, providing the first comprehensive look at the commercial performance of VIZZ® (aceclidine 1.44%).
Ocugen (NASDAQ:OCGN) today announced positive 12-month results from its Phase 2 ArMaDa clinical trial evaluating OCU410 (AAV-hRORA), a modifier gene therapy for the treatment of Geographic Atrophy (GA) secondary to dry Age-Related Macular Degeneration (dAMD).
NRx Pharmaceuticals (NASDAQ:NRXP) today reported its financial results and operational milestones for the full year ended December 31, 2025, highlighting a successful restructuring of its balance sheet and the transition into a revenue-generating entity.
Achieve Life Sciences (NASDAQ:ACHV) today reported its financial results for the fourth quarter and full year ended December 31, 2025, alongside a series of transformative regulatory and operational updates for its lead smoking cessation candidate, cytisinicline.
Karyopharm Therapeutics (NASDAQ:KPTI) today announced topline results from its global Phase 3 SENTRY clinical trial (n=353) evaluating the XPO1 inhibitor selinexor in combination with ruxolitinib (Jakafi®) for the frontline treatment of patients with myelofibrosis.
BioNTech (NASDAQ:BNTX) announced today its comprehensive participation in the European Lung Cancer Congress (ELCC) 2026, where the company will present updated data across its diversified lung cancer portfolio.
Radiopharm Theranostics (NASDAQ:RADX) today released a highly encouraging second interim data update from its ongoing U.S. Phase 2b clinical trial evaluating RAD 101, a novel FASN-targeting small-molecule imaging agent.
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous pemphigoid (BP) whose disease is not adequately controlled by existing therapies.
